La Jolla-based biopharmaceuticals startup Janux Therapeutics said early this morning that it has priced its IPO, offering up 11,400,000 shares of its common stock at $17.00 per share. The company begins trading this morning on the Nasdaq Global market under the ticker symbol JANX. According to the company, the gross proceeds from the effort are expected to be $193.8M. Janux Therapeutics is developing T cell engager immunotherapies. The company's biggest shareholders before the IPO were Avalon Ventures, RA Capital Healthcare, Orbimed, Bregua Corporation, and Correlation Ventures.